Live Breaking News & Updates on Hief development officer
Stay updated with breaking news from Hief development officer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript February 28, 2024 Amicus Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics’ Full Year 2023 Financial Results Conference […]
Anthony Grande, EVP, Chief Development Officer of CoreCivic Inc (NYSE:CXW), executed a sale of 15,000 shares in the company on February 26, 2024, according to a SEC Filing.
Standard Lithium Ltd. (AMEX:SLI) Q2 2024 Earnings Call Transcript February 12, 2024 Standard Lithium Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Krista and I’ll be your conference operator today. At this time, I […]
The Quad Cities Community Foundation has announced members of its Center for Nonprofit Excellence Advisory Committee. The committee is made up of 15 local leaders who will create the governance model for the center and carry forward its mission of strengthening regional nonprofits. The Center for Nonprofit Excellence is a new resource hub for the […]
Chief Development Officer Mohit Singh executed a sale of 174,000 shares of QuantumScape Corp (NYSE:QS) on January 4, 2024, according to a recent SEC Filing.
On December 28, 2023, Jeff Castelli, Chief Development Officer of Amicus Therapeutics Inc (NASDAQ:FOLD), sold 17,421 shares of the company's stock, according to a recent SEC Filing.
On December 20, 2023, Jeff Castelli, Chief Development Officer of Amicus Therapeutics Inc (NASDAQ:FOLD), sold 19,154 shares of the company, according to a recent SEC Filing.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2023 Earnings Call Transcript November 8, 2023 Amicus Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.08. Operator: Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics Third Quarter 2023 Financial Results Conference Call and webcast. [Operator Instructions] As a reminder, this conference is being […]